Why Cancer Doctors Stood and Applauded
Why It Matters
Directinib proves KRAS can be therapeutically targeted, offering a new lifeline for cancers that account for 20% of all cases and reshaping future treatment strategies.
Key Takeaways
- •New drug Directinib doubles median survival in metastatic pancreatic cancer.
- •Directinib targets KRAS by binding cyclophilin A, not mutation pocket.
- •KRAS mutations drive ~20% of all cancers, previously deemed undruggable.
- •Trial showed 13.2 months median survival versus 6.6 months with chemo.
- •Combination therapies with Directinib show high tumor shrinkage and progression‑free rates.
Summary
The video highlights a landmark phase‑III trial of Directinib, a novel KRAS inhibitor, that elicited a standing‑ovation from oncologists because it finally cracks a target long labeled “undruggable.”
In the study of 500 metastatic pancreatic‑cancer patients across six countries, oral Directinib extended median overall survival to 13.2 months versus 6.6 months for standard chemotherapy, effectively adding six months of life in a disease where five‑year survival is under 13%.
Unlike earlier KRAS drugs that only fit the rare G12C mutation, Directinib hijacks the abundant protein cyclophilin A to lock KRAS in its active state, shutting down signaling across multiple KRAS variants—including the dominant G12D in pancreatic tumors. The applause reflected both the survival gain and the proof‑of‑concept that KRAS can be drugged.
The breakthrough opens a pathway for treating roughly one‑fifth of all cancers driven by KRAS, and early combination studies pairing Directinib with agents targeting complementary vulnerabilities (e.g., MTAP loss) have shown tumor shrinkage in 11 of 12 patients. If replicated, this strategy could reshape therapeutic algorithms for pancreatic, lung, colorectal and other KRAS‑mutant malignancies.
Comments
Want to join the conversation?
Loading comments...